An interventional study of Zirconium dioxide nano-coated archwire and Conventional orthodontic archwire in Malocclusion of Anterior Teeth, sponsored by Al-Azhar University. Not yet recruiting. Open to participants aged 13 Years to 19 Years. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by Al-Azhar University · Not applicable, Interventional, and Treatment
"This clinical trial aims to evaluate the clinical performance and efficiency of zirconium dioxide nano-coated orthodontic archwires compared to conventional archwires. The study focuses on assessing the leveling and alignment duration, as well as evaluating patient comfort and clinical outcomes during the initial stages of orthodontic treatment."
323 studies on the registry are indexed under Malocclusion; 85 are open to participants now.
This study's planned enrollment of 20 is below the median of 37 across 242 interventional studies indexed under Malocclusion.
Browse Malocclusion studies →Al-Azhar University is the lead sponsor of 531 studies on the registry; 172 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients will receive orthodontic treatment using zirconium dioxide nano-coated archwires.
Device: Zirconium dioxide nano-coated archwire
Patients will receive conventional orthodontic archwires during treatment.
Device: Conventional orthodontic archwire
Zirconium dioxide nano-coated nickel-titanium archwire used during the leveling and alignment phase of fixed orthodontic treatment, compared against conventional uncoated NiTi archwires."
Conventional orthodontic archwire used during the leveling and alignment phase of fixed orthodontic treatment, compared against Zirconium dioxide nano-coated nickel-titanium archwire
Rate of dental alignment
Little's Irregularity Index (unabbreviated scale title). The index measures the linear displacement of the five anatomic points of the anterior teeth. Scores range from a minimum of 0 (representing perfect alignment with no displacement) to a maximum of 10 or higher (representing severe dental crowding and irregularity). Lower scores indicate a better outcome (greater dental alignment and successful leveling phase).
Time frame: Measured at baseline and every 4 weeks up to 16 weeks .
No study locations are listed for this record.
Plan to share: Yes — Yes, individual participant data that underlie the results reported in the publication will be shared after de-identification, beginning 3 months and ending 5 years following article publication, to researchers who provide a methodologically sound proposal
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Beginning 3 months and ending 5 years following article publication.
Access criteria: Requests should be directed to the corresponding author via email. Access will be granted to researchers whose proposed use of the data has been approved by an independent review committee for individual participant data meta-analyses.
Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.
Of 153 non-industry interventional studies with no phase under Malocclusion, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 30. This study's planned 12 months is below that.
Counting every sponsor, half of 163 studies reached it within 19 months; a quarter within 10 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.